Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 26;14(8):722.
doi: 10.3390/ph14080722.

Primary and Metastatic Brain Tumours Assessed with the Brain and Torso [18F]FDG PET/CT Study Protocol-10 Years of Single-Institutional Experiences

Agata Pietrzak  1   2 , Andrzej Marszałek  3 , Tomasz Piotrowski  1   4 , Adrianna Medak  1 , Katarzyna Pietrasz  2 , Julia Wojtowicz  5 , Hubert Szweda  4 , Krzysztof Matuszewski  4 , Witold Cholewiński  1   2
Affiliations
Review

Primary and Metastatic Brain Tumours Assessed with the Brain and Torso [18F]FDG PET/CT Study Protocol-10 Years of Single-Institutional Experiences

Agata Pietrzak et al. Pharmaceuticals (Basel). .

Abstract

According to the international societies' recommendations, the 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) technique should not be used as the method of choice in brain tumour diagnosis. Therefore, the brain region can be omitted during standard [18F]FDG PET/CT scanning. We performed comprehensive literature research and analysed results from 14,222 brain and torso [18F]FDG PET/CT studies collected in 2010-2020. We found 131 clinically silent primary and metastatic brain tumours and 24 benign lesions. We concluded that the brain and torso [18F]FDG PET/CT study provides valuable data that may support therapeutic management by detecting clinically silent primary and metastatic brain tumours.

Keywords: 18F-fluorodeoxyglucose; brain tumour; oncology; positron emission tomography.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of literature search methods (source: original figure).
Figure 2
Figure 2
Flow diagram of database collection (source: original figure).
Figure 3
Figure 3
Incidental finding of a hypodense and photopaenic area in the posterior part of the brain in the middle cranial fossa, consistent with arachnoid cyst, in a patient with cervical cancer (source: original figure). Description: axial view of the brain and torso [18F]FDG PET/CT over the middle cranial fossa—low-dose CT (left-hand side image), PET (middle image), and PET/CT fusion (right-hand side image).
Figure 4
Figure 4
Incidental finding of a hypodense and photopaenic area in the right parietal lobe, consistent with primary brain tumour, in a patient with larynx cancer (source: original figure). Description: axial view of the brain and torso [18F]FDG PET/CT over the middle cranial fossa—low-dose CT (left-hand side image), PET (middle image), and PET/CT fusion (right-hand side image).
Figure 5
Figure 5
A hyperdense and hypermetabolic mass in the right thalamus region, consistent with primary brain tumour (glioblastoma), in a patient with breast cancer (source: original figure). Description: axial view of the brain and torso [18F]FDG PET/CT over the middle cranial fossa—low-dose CT (left-hand side image), PET (middle image), and PET/CT fusion (right-hand side image).
Figure 6
Figure 6
Incidental finding of a left lobe cerebellum abnormal mass, consistent with unknown and clinically silent lung cancer solitary metastatic lesion (source: original figure). Description: axial view of the brain and torso [18F]FDG PET/CT over the cerebellum—low-dose CT (left-hand side image), PET (middle image), and PET/CT fusion (right-hand side image).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Stewart B.W., Wild C.P. Chapter 5.16. In: Kleihues P., Barnholtz-Sloan J., Ohgaki H., editors. World Cancer Report 2014. 1st ed. WHO Press; Geneva, Switzerland: 2015. pp. 511–520.
    1. Nieder C., Hintz M., Popp I., Bilger A., Grosu A.L. Long-term survival results after treatment for oligometastatic brain disease. Rep. Pract. Oncol. Radiother. 2020;25:307–311. doi: 10.1016/j.rpor.2020.03.001. - DOI - PMC - PubMed
    1. National Brain Tumor Society. [(accessed on 1 April 2021)]; Available online: https://braintumor.org/brain-tumor-information/
    1. Aldape K., Brindle K.M., Chesler L., Chopra R., Gajjar A., Gilbert M.R., Gottardo N., Gutmann D.H., Hargrave D., Holland E.C., et al. Challenges to curing primary brain tumours. Nat. Rev. Clin. Oncol. 2019;16:509–520. doi: 10.1038/s41571-019-0177-5. - DOI - PMC - PubMed
    1. Pope W.B. Brain metastases: Neuroimaging. Handb. Clin. Neurol. 2018;149:89–112. - PMC - PubMed

LinkOut - more resources